Welcome to our dedicated page for Sight Sciences news (Ticker: SGHT), a resource for investors and traders seeking the latest updates and insights on Sight Sciences stock.
Sight Sciences reports recurring developments as an eyecare technology company developing and commercializing interventional ophthalmic devices for glaucoma and dry eye disease. Its news commonly covers financial results and guidance, segment trends in Interventional Glaucoma and Interventional Dry Eye, and clinical data for the OMNI Surgical System and TearCare System.
Company updates also address investor conference participation, intellectual property matters involving interventional glaucoma patents, and product positioning across minimally invasive glaucoma surgery and evaporative dry eye treatment. News about SGHT centers on commercialization, reimbursement-sensitive procedure adoption, clinical evidence, and operating performance in its ophthalmic device portfolio.
Sight Sciences, a medical device company, successfully closed its initial public offering (IPO) on July 19, 2021, offering 11.5 million shares at $24.00 each. This includes the full exercise of underwriters' options for an additional 1.5 million shares, resulting in total gross proceeds of approximately $276 million. Trading of Sight Sciences shares commenced on the Nasdaq Global Market under the ticker symbol "SGHT" on July 15, 2021. The offering was managed by Morgan Stanley and BofA Securities, among others.
Sight Sciences has announced the pricing of its initial public offering (IPO) of 10 million shares at $24.00 per share, aiming for total proceeds of $240 million. The IPO is set to close on July 19, 2021, following its trading debut on Nasdaq under the symbol SGHT on July 15, 2021. The underwriters have a 30-day option to purchase up to 1.5 million additional shares. Morgan Stanley and BofA Securities are leading the offering with Citigroup and Piper Sandler also involved. This offering is a crucial step in Sight Sciences' growth strategy in the medical device market.